マーケットレポート詳細
ヒトマイクロバイオームの世界市場：2029年に至る疾患別、製品別予測
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029
- 出版元：MarketsandMarkets
出版元について - 発行年：2023年 5月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文 183ページになります。
- 商品コード：MAM3270
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
ヒトマイクロバイオームの世界市場規模は2023年で3億ドル、2029年に17億ドル、市場の平均年成長率は36.1%増加すると見込まれています。
レポートはヒトマイクロバイオームの世界市場について2029年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（用途別市場、疾患別市場、等）を中心に構成されています。また競合状況、主要企業情報（13社）、市場ダイナミクス、ファイブフォース分析なども加味し、ヒトマイクロバイオーム市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆ヒトマイクロバイオームの世界市場予測2023-2029年
・市場規模(US$)
◆用途別、市場-2029年
・治療
・診断
※(市場規模US$)
◆疾患別、市場-2029年
・感染症
・胃腸疾患
・内分泌、代謝性疾患
・がん
・その他疾患
※(市場規模US$)
◆製品別、市場-2029年
・医薬品
・診断検査
・プロバイオティクス
・プレバイオティクス
・その他製品
※(市場規模US$)
◆タイプ別、市場-2029年
・細菌コンソーシアム移植(BCT)/糞便微生物叢移植 (FMT)
・ペプチド
・腸内細菌製剤(LBPs)
・その他タイプ
※(市場規模US$)
◆主要国地域別市場-2029年
アジア太平洋
・日本、中国、インド
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・その他ヨーロッパ
その他地域
※国地域別に全セグメントの細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス(ドライバー、障壁、機会)
・競合状況
・エコシステム分析
・ファイブフォース分析
・サプライチェーン
・当局規制分析
・規制分析
・価格分析
◆ヒトマイクロバイオーム主要企業プロフィール動向
・ENTEROME
・D PHARMA PLC
・INTERNATIONAL FLAVORS & FRAGRANCES, INC
・OPTIBIOTIX HEALTH PLC
・FERRING PHARMACEUTICALS
・SYNLOGIC, INC
・SECOND GENOME INC
・VEDANTA BIOSCIENCES, INC
・YSOPIA BIOSCIENCE
・FLIGHTPATH BIOSCIENCES, INC
・FINCH THERAPEUTICS GROUP, INC
・AOBIOME THERAPEUTICS
・BIOGAIA
・QUANTBIOME, INC (DBA OMBRE)
その他企業
・VIOME LIFE SCIENCES, INC
・BIOHM HEALTH
・DAYTWO
・ALTAS BIOMED
・BIONE VENTURES PRIVATE LIMITED
・LUXIA SCIENTIFIC
・METABIOMICS
・SUN GENOMICS
・SEED HEALTH
・GNUBIOTICS SCIENCES
（全183頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE 26
1.4 YEARS CONSIDERED
1.5 CURRENCY
1.6 RESEARCH LIMITATIONS
1.7 STAKEHOLDERS
1.7.1 RECESSION IMPACT 27
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
・ FIGURE 1 HUMAN MICROBIOME MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
・ FIGURE 2 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
・ FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
・ FIGURE 4 HUMAN MICROBIOME MARKET SIZE, 2023 (USD MILLION)
・ FIGURE 5 HUMAN MICROBIOME MARKET: FINAL CAGR PROJECTIONS (2023−2029)
・ FIGURE 6 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET DATA ESTIMATION AND TRIANGULATION
2.3.1 DATA TRIANGULATION
・ FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
2.6 HUMAN MICROBIOME MARKET: GLOBAL RECESSION IMPACT
・ TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
・ TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
・ TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
・ FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)
・ FIGURE 9 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023 VS. 2029 (USD MILLION)
・ FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2023 VS. 2029 (USD MILLION)
・ FIGURE 11 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT
4 PREMIUM INSIGHTS
4.1 HUMAN MICROBIOME MARKET OVERVIEW
・ FIGURE 12 RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION AND COUNTRY (2023)
・ FIGURE 13 THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
4.3 HUMAN MICROBIOME MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
・ FIGURE 14 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
・ TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 COLLABORATIVE EFFORTS BETWEEN MICROBIOME INDUSTRY AND ACADEMIA FOR MICROBIOME RESEARCH
5.2.1.2 SURGING DEMAND FOR PERSONALIZED MEDICINE
5.2.1.3 RISING AWARENESS ABOUT IMPORTANCE OF HUMAN MICROBIOME
5.2.2 RESTRAINTS
5.2.2.1 ADVERSE IMPACT OF COMPLEX REGULATORY POLICIES ON COMMERCIALIZATION OF MICROBIOMES
5.2.3 OPPORTUNITIES
5.2.3.1 INCREASED COLLABORATION OF KEY PLAYERS AND SMALL INNOVATIVE COMPANIES TO WORK ON NEW MICROBIOME TECHNOLOGIES
・ TABLE 5 EXAMPLES OF COMPANY DEVELOPMENT
5.2.4 CHALLENGES
5.2.4.1 SLOW PATIENT ADOPTION OF MICROBIOME-BASED THERAPIES
5.2.4.2 COMPLEXITIES INVOLVED IN DEVELOPMENT OF MICROBIOME THERAPIES
5.3 TECHNOLOGY ANALYSIS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
・ FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 SUPPLY AND VALUE CHAIN ANALYSIS
5.5.1 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS
・ FIGURE 17 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS
5.5.2 VALUE CHAIN ANALYSIS OF HUMAN MICROBIOME MARKET
・ FIGURE 18 HUMAN MICROBIOME MARKET: VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
・ FIGURE 19 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
・ TABLE 6 HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY ANALYSIS
5.8.1 FDA APPROVALS
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PRICING ANALYSIS
・ TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT
5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS
5.10 KEY CONFERENCES AND EVENTS IN 2023
5.10.1 HUMAN MICROBIOME CONFERENCES (2023)
・ TABLE 12 HUMAN MICROBIOME CONFERENCES (2023)
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
・ FIGURE 20 HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
5.11.2 HUMAN MICROBIOME MARKET: BUYING CRITERIA
・ FIGURE 21 KEY BUYING CRITERIA FOR HEALTH SUPPLEMENTS AND MEDICAL FOODS
6 HUMAN MICROBIOME MARKET, BY APPLICATION
6.1 INTRODUCTION
・ TABLE 13 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
6.2 THERAPEUTICS
6.2.1 AVAILABILITY OF FUNDING FOR DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET 62
・ TABLE 14 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 15 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 16 EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 17 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3 DIAGNOSTICS 65
6.3.1 INCREASE IN FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET
・ TABLE 18 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 19 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 20 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 21 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION)
7 HUMAN MICROBIOME MARKET, BY DISEASE
7.1 INTRODUCTION
・ TABLE 22 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
7.2 INFECTIOUS DISEASES
7.2.1 RISE IN CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO BOOST MARKET
・ TABLE 23 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
・ TABLE 24 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 25 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 26 EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 27 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 72
7.3 GASTROINTESTINAL DISEASES
7.3.1 SPIKE IN CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO PROPEL MARKET
・ TABLE 28 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 29 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 30 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
7.4 ENDOCRINE & METABOLIC DISORDERS
7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO BOOST MARKET
・ TABLE 32 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR ENDOCRINE & METABOLIC DISORDERS
・ TABLE 33 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2029 (USD MILLION) 75
・ TABLE 34 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 35 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
7.5 CANCER
7.5.1 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR TREATMENT OF PELVIC AND COLON CANCER TO DRIVE MARKET 76
・ TABLE 37 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 38 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 39 EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 40 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)
7.6 OTHER DISEASES
・ TABLE 41 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 42 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 43 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 44 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
8 HUMAN MICROBIOME MARKET, BY PRODUCT
8.1 INTRODUCTION
・ TABLE 45 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION))
8.2 DRUGS
8.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS TO DRIVE MARKET
・ TABLE 46 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)
8.3 DIAGNOSTIC TESTS
8.3.1 GROWING CONSUMER AWARENESS OF MICROBIOME-BASED TESTS TO BOOST MARKET
・ TABLE 50 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 51 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 52 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 53 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
8.4 PROBIOTICS 85
8.4.1 GROWING RESEARCH ON PROBIOTICS TO PROMOTE CREDIBILITY IN HEALTH CLAIMS AND SAFETY
・ TABLE 54 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 56 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
8.5 PREBIOTICS 87
8.5.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH
・ TABLE 58 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 59 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 60 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 61 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
8.6 OTHER PRODUCTS
・ TABLE 62 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 63 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 64 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 65 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
9 HUMAN MICROBIOME MARKET, BY TYPE
9.1 INTRODUCTION
・ TABLE 66 HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
9.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
9.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH
・ TABLE 67 HUMAN MICROBIOME MARKET FOR BCT/FMT, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 69 EUROPE: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION)
9.3 PEPTIDES
9.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO DRIVE MARKET
・ TABLE 71 HUMAN MICROBIOME MARKET FOR PEPTIDES, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 72 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 73 EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 74 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION)
9.4 LIVE BIOTHERAPEUTIC PRODUCTS
9.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET
・ TABLE 75 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 76 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 77 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 78 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
9.5 OTHER TYPES 99
・ TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY REGION, 2023–2029 (USD MILLION)
・ TABLE 80 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 81 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION)
10 HUMAN MICROBIOME MARKET, BY REGION
10.1 INTRODUCTION
・ FIGURE 22 HUMAN MICROBIOME MARKET, BY REGION, 2023 VS. 2029 (USD MILLION)
・ TABLE 83 HUMAN MICROBIOME MARKET, BY REGION, 2023–2029 (USD MILLION)
10.2 NORTH AMERICA
・ FIGURE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
・ TABLE 84 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 85 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 86 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 87 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.2.1 US
10.2.1.1 SPIKE IN RESEARCH ACTIVITIES TO DRIVE MARKET
・ TABLE 88 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 89 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 90 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 91 US: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.2.2 CANADA
10.2.2.1 RISING PREVALENCE OF CHRONIC DISEASES TO BOOST MICROBIOME RESEARCH
・ TABLE 92 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 93 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 94 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 95 CANADA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.2.3 NORTH AMERICA: RECESSION IMPACT
10.3 EUROPE
・ TABLE 96 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 97 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 98 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 99 EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 RAPID INCREASE IN GOVERNMENT FUNDING TO PROPEL MARKET
・ TABLE 100 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 101 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 102 GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 103 GERMANY: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.3.2 UK
10.3.2.1 SIGNIFICANT GOVERNMENT INVESTMENTS IN GENOMICS RESEARCH TO PROPEL GROWTH
・ TABLE 104 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 105 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 106 UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 107 UK: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 RISE IN MICROBIOME SEQUENCING STARTUPS TO BOOST GROWTH
・ TABLE 108 HUMAN MICROBIOME STARTUPS IN FRANCE
・ TABLE 109 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 110 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 111 FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 112 FRANCE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.3.4 REST OF EUROPE
・ TABLE 113 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 114 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 115 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 116 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.3.5 EUROPE: IMPACT OF RECESSION 119
10.4 ASIA PACIFIC
・ FIGURE 24 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
・ TABLE 117 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
・ TABLE 118 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 119 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 120 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 121 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.4.1 CHINA
10.4.1.1 INCREASING R&D INVESTMENTS TO DRIVE GROWTH
・ TABLE 122 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 123 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 124 CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 125 CHINA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 GROWING GERIATRIC POPULATION TO PRESENT OPPORTUNITIES FOR MARKET GROWTH
・ TABLE 126 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 127 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 128 JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 129 JAPAN: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.4.3 INDIA
10.4.3.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH
・ TABLE 130 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 131 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 132 INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 133 INDIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
・ TABLE 134 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 135 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 136 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 137 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.4.5 ASIA PACIFIC: RECESSION IMPACT
10.5 REST OF THE WORLD
・ TABLE 138 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
・ TABLE 139 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
・ TABLE 140 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
・ TABLE 141 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
10.5.1 REST OF THE WORLD: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY STRATEGIES ADOPTED BY PLAYERS
・ FIGURE 25 HUMAN MICROBIOME MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
11.3 COMPANY EVALUATION QUADRANT
・ FIGURE 26 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (2022)
11.3.1 STARS
11.3.2 EMERGING LEADERS
11.3.3 PERVASIVE PLAYERS
11.3.4 PARTICIPANTS
11.4 COMPANY EVALUATION QUADRANT: START-UPS/SMES
11.4.1 PROGRESSIVE COMPANIES
11.4.2 STARTING BLOCKS
11.4.3 RESPONSIVE COMPANIES
11.4.4 DYNAMIC COMPANIES
・ FIGURE 27 HUMAN MICROBIOME MARKET: START-UPS/SMES EVALUATION QUADRANT (2022)
11.4.5 COMPETITIVE BENCHMARKING
11.4.5.1 HUMAN MICROBIOME MARKET: DETAILED LIST OF START-UPS/SMES
・ TABLE 142 HUMAN MICROBIOME MARKET: DETAILED LIST OF START-UPS/SMES
11.4.5.2 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
・ TABLE 143 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
11.5 COMPETITIVE SCENARIO AND TRENDS
・ TABLE 144 HUMAN MICROBIOME MARKET: DEALS
11.5.1 PRODUCT LAUNCHES
・ TABLE 145 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES
11.5.2 EXPANSIONS
・ TABLE 146 HUMAN MICROBIOME MARKET: EXPANSIONS
12 COMPANY PROFILES
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
12.1 KEY PLAYERS 145
12.1.1 SERES THERAPEUTICS, INC.
・ TABLE 147 SERES THERAPEUTICS, INC.: COMPANY OVERVIEW
12.1.2 ENTEROME
・ TABLE 148 ENTEROME: COMPANY OVERVIEW 148
12.1.3 4D PHARMA PLC
・ TABLE 149 4D PHARMA: COMPANY OVERVIEW 151
・ FIGURE 29 4D PHARMA: COMPANY SNAPSHOT (2022)
12.1.4 INTERNATIONAL FLAVORS & FRAGRANCES, INC.
・ TABLE 150 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW
・ FIGURE 30 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2022)
12.1.5 OPTIBIOTIX HEALTH PLC
・ TABLE 151 OPTIBIOTIX: COMPANY OVERVIEW 157
・ FIGURE 31 OPTIBIOTIX: COMPANY SNAPSHOT (2021)
12.1.6 FERRING PHARMACEUTICALS
・ TABLE 152 FERRING PHARMACEUTICALS: COMPANY OVERVIEW
12.1.7 SYNLOGIC, INC.
・ TABLE 153 SYNLOGIC, INC.: COMPANY OVERVIEW
・ FIGURE 32 SYNLOGIC, INC: COMPANY SNAPSHOT (2022)
12.1.8 SECOND GENOME INC.
・ TABLE 154 SECOND GENOME INC.: COMPANY OVERVIEW
12.1.9 VEDANTA BIOSCIENCES, INC.
・ TABLE 155 VEDANTA BIOSCIENCES: COMPANY OVERVIEW
12.1.10 YSOPIA BIOSCIENCE
・ TABLE 156 YSOPIA BIOSCIENCE: COMPANY OVERVIEW
12.1.11 FLIGHTPATH BIOSCIENCES, INC. 170
・ TABLE 157 FLIGHTPATH BIOSCIENCES, INC.: COMPANY OVERVIEW
12.1.12 FINCH THERAPEUTICS GROUP, INC.
・ TABLE 158 FINCH THERAPEUTICS: COMPANY OVERVIEW
・ FIGURE 33 FINCH THERAPEUTICS: COMPANY SNAPSHOT (2022)
12.1.13 AOBIOME THERAPEUTICS
・ TABLE 159 AOBIOME THERAPEUTICS: COMPANY OVERVIEW
12.1.14 BIOGAIA
・ TABLE 160 BIOGAIA: COMPANY OVERVIEW
・ FIGURE 34 BIOGAIA: COMPANY SNAPSHOT (2021)
12.1.15 QUANTBIOME, INC. (DBA OMBRE) 177
・ TABLE 161 QUANTBIOME, INC.: COMPANY OVERVIEW
12.2 OTHER PLAYERS
12.2.1 VIOME LIFE SCIENCES, INC.
12.2.2 BIOHM HEALTH
12.2.3 DAYTWO
12.2.4 ALTAS BIOMED
12.2.5 BIONE VENTURES PRIVATE LIMITED
12.2.6 LUXIA SCIENTIFIC
12.2.7 METABIOMICS
12.2.8 SUN GENOMICS
12.2.9 SEED HEALTH
12.2.10 GNUBIOTICS SCIENCES
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.